Aldehyde dehydrogenase-1 expression and prognosis in triple-negative breast cancer

Murrja, Edvin; Turna, Zeynep Hande; Öztürk, Mehmet Akif; Cinkaya, Ahmet; Öztürk, Tülin

doi:10.17546/msd.82203

Cited by 2 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to AJCC TNM stage grouping, stage III was the dominant stage Thirty-one cases, constituting (51.67%) of the cases, and only 3 cases were stage I (5%) these agreed with Atwa et al [26] who found that 60% of the patients with stage III. These results are quite different from those reported by Edvin et al [27] stated that the majority of their TNBC cases with stage II.…”

Section: Figure 5: Strong Expression Of Aldh1a1 In Metastatic Lymph N...contrasting

confidence: 96%

“…Regarding the relation between AJCC TNM stage grouping and ALDH1A1 expression, 88.5% of Stage II tumors and 87.1% of stage III tumors showed positive immunostaining; however, no significant correlation was seen (p = 0.801). This in agreement with other studies conducted by Edvin et al [27] and Atwa et al [26].…”

Section: Figure 5: Strong Expression Of Aldh1a1 In Metastatic Lymph N...supporting

confidence: 94%

See 1 more Smart Citation

Stem Cell Marker Aldehyde Dehydrogenase 1A1 Expression in Triple-negative Breast Carcinoma

Mohamed

Ibrahim

Sheikh

et al. 2022

Open Access Maced J Med Sci

View full text Add to dashboard Cite

Background: Increasing evidence has proposed that tumor contains tumor initiating cells or cancer stem cells (CSCs) are responsible for its progression and relapse. Aldehyde dehydrogenase 1A1 (ALDH1A1) has recently been identified as a marker for cancer stem cells in some human malignancies including breast cancer.Triple negative breast carcinomas (TNBCs) are group of primary breast tumors with aggressive clinical behavior that have no targeted therapy at present. Aim: The assessment of immunohistochemical expression of ALDH1A1 in triple negative breast carcinoma and its correlation with the clinicopathological features of TNBC. Material and Methods: This study consisted of 60 cases of TNBC. Immunohistochemical reactions were carried out by using ALDH1A1 monoclonal antibody. A total score of ALDH1A1 expression is obtained by multiplying the score of staining intensity & percentage of stained cells to obtain score ranging from 0 up to 300. Due to the relatively large number of positive cases, a statistical analysis was performed with a negative (score ≤ 10) and positive (score > 10) cutoff [1]. Results: Evaluation of the results of immunostaining for ALDH1A1 showed 88.3% of totalcases (53 cases) having a positive cytoplasmic reactivity. Statistical analysis for a possible correlation between ALDH1A1 expression and prognostic clinicopathological parameters; age, size, tumor grade, histologic subtypes, lymphovascular invasion, intraductal components, tumor infiltrating lymphocytes and TNM stage grouping revealed a non-significant correlation. Conclusion: ALDH1A1 couldn’t be used solely as a diagnostic or prognostic marker In TNBCs. Further research combining with other biomarkers and with a greater number of patients is necessary to confirm the role of ALDH1A1 in TNBC. Key words: Cancer stem cells (CSCs), Aldehyde dehydrogenase 1A1 (ALDH1A1), Triple Negative Breast cancer (TNBC).

show abstract

Section: Figure 5: Strong Expression Of Aldh1a1 In Metastatic Lymph N...contrasting

confidence: 96%

Section: Figure 5: Strong Expression Of Aldh1a1 In Metastatic Lymph N...supporting

confidence: 94%

Stem Cell Marker Aldehyde Dehydrogenase 1A1 Expression in Triple-negative Breast Carcinoma

Mohamed

Ibrahim

Sheikh

et al. 2022

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

ALDH 1A1 and caveolin-1 expression in triple negative breast cancer

Atwa

Ibrahim

Ismail

et al. 2017

Oncology and Translational Medicine

View full text Add to dashboard Cite

ObjectiveTriple negative breast cancer (TNBC) contains a high proportion of breast cancer stem cells (BCSCs) and exhibits resistance to chemotherapy treatments. Therefore, the identification of BCSCs that are novel molecular targets may improve patient survival. Aldehyde dehydrogenase-1 (ALDH 1A1) has been considered a cancer stem cell marker in different tumors. Caveolin-1 (Cav-1), a membrane transporter protein, regulates cancer chemo-resistance and stem cell signaling. Thus, the aim of this study was to evaluate the expression of ALDH 1A1 and Cav-1 in patients with TNBC by immunohistochemistry (IHC) and to correlate their expression with clinical and pathological parameters.MethodsParaffin blocks of 30 breast cancer patients who underwent modified radical mastectomy between January 2013 and December 2016 in Zagazig University Hospitals (Egypt) were evaluated. Antibodies to ALDH 1A1 and Cav-1 were used.ResultsALDH 1A1 and Cav-1 significantly correlated with tumor size. A significant association between ALDH 1A1/Cav-1 IHC staining and relapse was found. Cav-1 and ALDH 1A1-positive expression correlated with a short 3-year disease-free survival rate and a 3-year overall survival rate (P < 0.001).ConclusionALDH 1A1 and Cav-1 expression in TNBC was significantly positively correlated with poor clinicopathological parameters and shortened survival. Expression of both markers was significantly positively correlated with each other (P < 0.001). ALDH 1A1 and Cav-1 could be potential therapeutic targets in breast cancer.

show abstract

Aldehyde dehydrogenase-1 expression and prognosis in triple-negative breast cancer

Cited by 2 publications

References 24 publications

Stem Cell Marker Aldehyde Dehydrogenase 1A1 Expression in Triple-negative Breast Carcinoma

Stem Cell Marker Aldehyde Dehydrogenase 1A1 Expression in Triple-negative Breast Carcinoma

ALDH 1A1 and caveolin-1 expression in triple negative breast cancer

Contact Info

Product

Resources

About